These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 39111110)

  • 1. Unfavorable carcinoma of unknown primary with a gastrointestinal profile: a retrospective study.
    Guidi L; Valenza C; Battaiotto E; Trapani D; Ghioni MC; Crimini E; Boscolo Bielo L; Venetis K; Belli C; Bottiglieri L; Gervaso L; Cella CA; Ciardiello D; Spada F; Benini L; Adorisio R; Mane E; Fazio N; Guerini Rocco E; Curigliano G; Zampino MG
    ESMO Open; 2024 Aug; 9(8):103662. PubMed ID: 39111110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology.
    Boscolo Bielo L; Belli C; Crimini E; Repetto M; Ascione L; Pellizzari G; Santoro C; Fuorivia V; Barberis M; Fusco N; Rocco EG; Curigliano G
    Oncologist; 2024 Jun; 29(6):504-510. PubMed ID: 38520742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carcinoma of unknown primary with gastrointestinal profile: immunohistochemistry and survival data for this favorable subset.
    Varadhachary GR; Karanth S; Qiao W; Carlson HR; Raber MN; Hainsworth JD; Greco FA
    Int J Clin Oncol; 2014; 19(3):479-84. PubMed ID: 23813044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective analysis of clinical characteristics and outcomes of patients with carcinoma of unknown primary from three tertiary centers in Australia.
    Boys EL; Gao B; Grimison P; Sutherland S; MacKenzie KL; Reddel RR; Liu J
    Cancer Med; 2024 Mar; 13(6):e7052. PubMed ID: 38523552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impact of Poorly Differentiated Histology on Immunotherapy in Advanced Gastrointestinal Cancers.
    Draper A; Jung EH; Cao Y; Atallah RP; Switchenko J; Kane S; Guadagno J; Jones AT; Brutcher E; Alese OB
    Oncology; 2023; 101(4):213-223. PubMed ID: 36626879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical presentation of carcinoma of unknown primary: 14 years of experience.
    Yi JH; La Choi Y; Lee SJ; Ahn HK; Baek KK; Lim T; Lee DJ; Han BR; Lee HY; Jun HJ; Lee J; Park YH
    Tumour Biol; 2011 Feb; 32(1):45-51. PubMed ID: 20697986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site.
    Kodaira M; Yonemori K; Shimoi T; Yoshida A; Yoshida M; Kitano A; Shimomura A; Yunokawa M; Shimizu C; Takiguchi Y; Fujiwara Y; Tamura K
    BMC Cancer; 2018 Feb; 18(1):176. PubMed ID: 29433539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relevance of the time interval between surgery and adjuvant radio (chemo) therapy in HPV-negative and advanced head and neck carcinoma of unknown primary (CUP).
    Balk M; Rupp R; Mantsopoulos K; Allner M; Grundtner P; Mueller SK; Traxdorf M; Eckstein M; Speer S; Semrau S; Fietkau R; Iro H; Hecht M; Gostian AO
    BMC Cancer; 2021 Nov; 21(1):1236. PubMed ID: 34794411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and immune profiling for cancer of unknown primary site.
    Haratani K; Hayashi H; Takahama T; Nakamura Y; Tomida S; Yoshida T; Chiba Y; Sawada T; Sakai K; Fujita Y; Togashi Y; Tanizaki J; Kawakami H; Ito A; Nishio K; Nakagawa K
    J Immunother Cancer; 2019 Sep; 7(1):251. PubMed ID: 31519206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial.
    Hayashi H; Takiguchi Y; Minami H; Akiyoshi K; Segawa Y; Ueda H; Iwamoto Y; Kondoh C; Matsumoto K; Takahashi S; Yasui H; Sawa T; Onozawa Y; Chiba Y; Togashi Y; Fujita Y; Sakai K; Tomida S; Nishio K; Nakagawa K
    JAMA Oncol; 2020 Dec; 6(12):1931-1938. PubMed ID: 33057591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of cancer of unknown primary, today and future].
    Shibata H
    Gan To Kagaku Ryoho; 2009 Jun; 36(6):918-22. PubMed ID: 19542712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of patients diagnosed with cancer of unknown primary or malignancy of undefined primary origin who were referred to a regional cancer center.
    Ando M; Honda K; Hosoda W; Matsubara Y; Kumanishi R; Nakazawa T; Ogata T; Nakata A; Kodama H; Masuishi T; Narita Y; Taniguchi H; Kadowaki S; Muro K
    Int J Clin Oncol; 2023 May; 28(5):644-653. PubMed ID: 36899286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of prognostic factors in 68 patients with cancer of unknown primary site].
    Kou XG; Liang DL; Zhang QQ; Li XR; Zhao YZ; Gu JF; Lu P
    Zhonghua Zhong Liu Za Zhi; 2011 Oct; 33(10):783-6. PubMed ID: 22335913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective analysis of definitive radiotherapy for neck node metastasis from unknown primary tumor: Japanese Radiation Oncology Study Group study.
    Yamazaki T; Kodaira T; Ota Y; Akimoto T; Wada H; Hiratsuka J; Nishimura Y; Ishihara S; Nonoshita T; Hayakawa K; Sekii S; Uchida N
    Jpn J Clin Oncol; 2017 Sep; 47(9):856-862. PubMed ID: 28903529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
    Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
    Oncologist; 2012; 17(1):13. PubMed ID: 22210086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic clinicopathologic factors in carcinoma of unknown primary origin: a study of 106 consecutive cases.
    Choi J; Nahm JH; Kim SK
    Oncotarget; 2017 Sep; 8(37):62630-62640. PubMed ID: 28977975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors among patients with brain metastases from cancer of unknown primary site.
    Simões Padilla C; Ho VKY; van der Strate IH; Leenders WPJ; de Vos FYFL; Veldhuijzen van Zanten SEM; Loef C
    J Neurooncol; 2022 Sep; 159(3):647-655. PubMed ID: 35976548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analysis of sequential chemotherapy efficacy in ovarian epithelial carcinoma, fallopian tube carcinoma and primary peritoneal carcinoma].
    Shen XY; Li XP; Wang Y; Wu Y; Li Y; Yang YC; Wei LH; Fan Y; Tang ZQ
    Zhonghua Fu Chan Ke Za Zhi; 2024 May; 59(5):383-390. PubMed ID: 38797568
    [No Abstract]   [Full Text] [Related]  

  • 19. Bone metastasis is associated with poor prognosis in metastatic papillary renal cell carcinoma patients treated with first agent angiogenesis inhibitors.
    Haaker L; Tryssesoone L; Renders I; Verbiest A; Lerut E; Baldewijns M; Bourgain C; Roussel E; Van den Bulck H; Wynendaele W; Laguerre B; Rioux-Leclercq N; Oudard S; Laenen A; Debruyne PR; Albersen M; Beuselinck B
    Urol Oncol; 2020 Aug; 38(8):686.e1-686.e9. PubMed ID: 32430250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A matched comparison of human papillomavirus-induced squamous cancer of unknown primary with early oropharynx cancer.
    Ross RB; Koyfman SA; Reddy CA; Houston N; Geiger JL; Woody NM; Joshi NP; Greskovich JF; Burkey BB; Scharpf J; Lamarre ED; Prendes B; Lorenz RR; Adelstein DJ; Ward MC
    Laryngoscope; 2018 Jun; 128(6):1379-1385. PubMed ID: 29086413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.